Justine Yang Bruce

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. pmc Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography
    Justine Yang Bruce
    Department of Medicine, University of Wisconsin Carbone Cancer Center, 7105 Wisconsin Institute Medical Research, 1111 Highland Ave, Madison, WI, 53705, USA
    Cancer Chemother Pharmacol 76:187-95. 2015
  2. pmc A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
    Justine Yang Bruce
    Section of Hematology Oncology, University of Wisconsin Carbone Cancer Center, 1111 Highland Avenue, Rm 7105, Madison, WI, 53705, USA
    Cancer Chemother Pharmacol 73:485-93. 2014
  3. pmc A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate
    Justine Yang Bruce
    Section of Hematology Oncology, University of Wisconsin Carbone Cancer Center, Wisconsin Institutes for Medical Research, Room 7105, 1111 Highland Avenue, Madison, WI 53705, USA
    Invest New Drugs 30:794-802. 2012
  4. ncbi request reprint Current controversies in the management of biochemical failure in prostate cancer
    Justine Yang Bruce
    Division of Hematology Oncology, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705 2275, USA
    Clin Adv Hematol Oncol 10:716-22. 2012

Detail Information

Publications4

  1. pmc Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography
    Justine Yang Bruce
    Department of Medicine, University of Wisconsin Carbone Cancer Center, 7105 Wisconsin Institute Medical Research, 1111 Highland Ave, Madison, WI, 53705, USA
    Cancer Chemother Pharmacol 76:187-95. 2015
    ..Rapid disease progression associated with increased tumor proliferation has been observed during withdrawal of anti-angiogenic therapy. We characterize the dynamics of withdrawal flare for axitinib...
  2. pmc A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies
    Justine Yang Bruce
    Section of Hematology Oncology, University of Wisconsin Carbone Cancer Center, 1111 Highland Avenue, Rm 7105, Madison, WI, 53705, USA
    Cancer Chemother Pharmacol 73:485-93. 2014
    ..We evaluated a sequential design administering bevacizumab during the sunitinib treatment break to suppress the sunitinib withdrawal flare...
  3. pmc A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate
    Justine Yang Bruce
    Section of Hematology Oncology, University of Wisconsin Carbone Cancer Center, Wisconsin Institutes for Medical Research, Room 7105, 1111 Highland Avenue, Madison, WI 53705, USA
    Invest New Drugs 30:794-802. 2012
    ....
  4. ncbi request reprint Current controversies in the management of biochemical failure in prostate cancer
    Justine Yang Bruce
    Division of Hematology Oncology, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705 2275, USA
    Clin Adv Hematol Oncol 10:716-22. 2012
    ..Other management approaches under investigation include intermittent ADT, the combination of ADT and novel agents, and peripheral androgen blockade...